Essential Partners
INDV icon

Essential Partners’s Indivior Pharmaceuticals INDV Stock Holding History

Essential Partners’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$609 Hold
17
– – ﹤0.01% 2335
2026
Q2 		$698 Hold
17
– – ﹤0.01% 2392
2026
Q1 		$518 Sell
17
-61
-78% -$2.02K ﹤0.01% 2427
2025
Q4 		$2.8K Buy
78
+74
+1,850% +$2.26K ﹤0.01% 1681
2025
Q3 		$96 Buy
+4
New +$84 ﹤0.01% 2498

Other funds holding INDV

Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
BI Asset Management Fondsmaeglerselskab
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Louisiana State Employees Retirement System
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

Essential Partners's INDV Position: Q3 2026 in Review

Essential Partners held its Indivior Pharmaceuticals (INDV) position steady in Q3 2026 at 17 shares worth $609. The position accounts for ﹤0.01% of the portfolio, ranked #2335.

Essential Partners first reported a position in INDV in Q3 2025 and has held it in 5 quarters since. The position peaked at $2.8K in Q4 2025. 40 funds tracked by Wall St. Rank hold INDV as of Q3 2026.

  • Essential Partners held 17 shares of Indivior Pharmaceuticals worth $609 as of Q3 2026.
  • Essential Partners left its Indivior Pharmaceuticals share count unchanged in Q3 2026.
  • Indivior Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2335 holding.
  • Essential Partners first reported a position in Indivior Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • Essential Partners's Indivior Pharmaceuticals position peaked at $2.8K in Q4 2025.
  • 40 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.